La cadena de opciones muestra datos clave de las opciones de acciones de ChromaDex a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para ChromaDex..

ChromaDex (NASDAQ:CDXC) Bolsa, Cadena de Opciones

ChromaDex

ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.

ChromaDex Corp

<h3>Gainers</h3>
<ul>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) stock rose 28.5% to $0.55 during Thursday's after-market session. The market value of their outstanding shares is at $21.0 million. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares increased by 28.08% to $1.87. The company's market cap stands at $2.5 million. </li>
<li>Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) shares increased by 19.69% to $37.13. The market value of their outstanding shares is at $124.6 million. </li>
<li>ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) stock increased by 18.62% to $4.14. The market value of their outstanding shares is at $314.3 million. As per the news, the Q3 earnings report came out today. </li>
<li>Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) stock moved upwards by 7.7% to $54.49. The company's market cap stands at $6.9 billion. The company's, Q3 earnings came out today. </li>
<li>Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) shares rose 7.49% to $6.31. The company's market cap stands at $1.4 billion. The company's, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) stock decreased by 10.6% to $1.1 during Thursday's after-market session. The company's market cap stands at $6.0 million. </li>
<li>BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) stock decreased by 5.74% to $1.47. The market value of their outstanding shares is at $10.1 million. </li>
<li>Palisade Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) stock decreased by 5.52% to $2.57. The company's market cap stands at $3.0 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares fell 5.49% to $7.75. The company's market cap stands at $18.6 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares fell 5.23% to $0.83. The company's market cap stands at $28.8 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock decreased by 5.12% to $1.67. The market value of their outstanding shares is at $15.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ARDX

ATHA

BFRI

BRTX

CDXC

HALO

LUCY

OCEA

PALI

PDEX

TOVX

TRIB

12 Health Care Stocks Moving In Thursday's After-Market Session

WIIM

ChromaDex shares are trading higher after the company reported a year-over-year increase in Q3 EPS results and raised its FY24 revenue guidance.

ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) raises FY2024 sales outlook from $91.93 million-96.11 million to $96.11 million.

News

Guidance

ChromaDex Raises FY2024 Sales Guidance from $91.93M-96.11M to $96.11M.

ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) reported quarterly earnings of $0.02 per share. This is a 300 percent increase over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $25.58 million which beat the analyst consensus estimate of $23.64 million by 8.21 percent. This is a 31.21 percent increase over sales of $19.50 million the same period last year.

Earnings

Earnings Beats

ChromaDex Q3 EPS $0.02 Up From $(0.01) YoY, Sales $25.58M Beat $23.64M Estimate

ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) is gearing up to announce its quarterly earnings on Thursday, 2024-10-31. Here's a quick overview of what investors should know before the release.
Analysts are estimating that ChromaDex will report an earnings per share (EPS) of $0.00.
Investors in ChromaDex are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.02, leading to a 9.51% increase in the share price on the subsequent day.
Here's a look at ChromaDex's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.02</td>
<td>-0.02</td>
<td>-0.03</td>
<td>-0.03</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0</td>
<td>-0.01</td>
<td>0</td>
<td>-0.01</td>
</tr>
<tr>
<td>Price Change %</td>
<td>10.0%</td>
<td>-8.0%</td>
<td>-8.0%</td>
<td>-11.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730322267_0.png" alt="eps graph" />
<h3>Insights Shared by Analysts on ChromaDex</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on ChromaDex.
ChromaDex has received a total of 1 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $6.0, the consensus suggests a potential 65.75% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Codexis, Lifecore Biomedical and Personalis, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>The consensus among analysts is an Outperform trajectory for Codexis, with an average 1-year price target of $11.0, indicating a potential 203.87% upside.</li>
<li>For Lifecore Biomedical, analysts project an Buy trajectory, with an average 1-year price target of $8.0, indicating a potential 120.99% upside.</li>
<li>For Personalis, analysts project an Buy trajectory, with an average 1-year price target of $7.75, indicating a potential 114.09% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Codexis, Lifecore Biomedical and Personalis, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>ChromaDex</td>
<td>Buy</td>
<td>11.89%</td>
<td>$13.69M</td>
<td>-0.05%</td>
</tr>
<tr>
<td>Codexis</td>
<td>Outperform</td>
<td>-62.58%</td>
<td>$4.52M</td>
<td>-32.34%</td>
</tr>
<tr>
<td>Lifecore Biomedical</td>
<td>Buy</td>
<td>0.75%</td>
<td>$5.39M</td>
<td>-440.02%</td>
</tr>
<tr>
<td>Personalis</td>
<td>Buy</td>
<td>35.22%</td>
<td>$8.04M</td>
<td>-10.99%</td>
</tr>
</tbody>
</table>

Key Takeaway:
ChromaDex ranks highest in revenue growth among its peers. It also leads in gross profit margin. However, it has the lowest return on equity. Overall, ChromaDex is positioned at the top compared to its peers in terms of revenue growth and gross profit, but lags behind in return on equity.
<h3>Get to Know ChromaDex Better</h3>
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.
<h3>Understanding the Numbers: ChromaDex's Finances</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: ChromaDex's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 11.89%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: ChromaDex's net margin excels beyond industry benchmarks, reaching -0.07%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): ChromaDex's ROE stands out, surpassing industry averages. With an impressive ROE of -0.05%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): ChromaDex's ROA stands out, surpassing industry averages. With an impressive ROA of -0.03%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: ChromaDex's debt-to-equity ratio is below the industry average at 0.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/CDXC/earnings">To track all earnings releases for ChromaDex visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into ChromaDex's Upcoming Earnings

Management

ChromaDex Names Ozan Pamir As CFO

Biotech

General

ChromaDex Expands Distribution Of Niagen+ IV And Injections To 14 New Wellness Clinics; Wells Pharma To Compound And Distribute Pharmaceutical-Grade Niagen Following Successful Initial Launch

Legal

ChromaDex Granted  U.S. Patent Number 10,000,520 C1 Covering The Composition Of Matter For The Disodium Salt Of NMNH

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) with a Buy and maintains $6 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on ChromaDex, Maintains $6 Price Target

Prior guidance: &quot;Looking forward, for the full year, the Company expects the trajectory of full year revenue growth to continue, projecting a higher rate of revenue growth than the prior year growth of&nbsp;16%.&quot;
The Company projects that gross margin will improve slightly year-over-year. The Company plans to continue to invest in research and development to drive future innovation and expects general and administrative expense to be down&nbsp;$1.5 million&nbsp;year over year.

ChromaDex Now Expects FY24 Revenue Growth Of 10% - 15%  Y/Y

ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) reported quarterly sales of $22.739 million which missed the analyst consensus estimate of $23.437 million by 2.98 percent. This is a 11.89 percent increase over sales of $20.323 million the same period last year.

Earnings Misses

ChromaDex Q2 Sales $22.739M Miss $23.437M Estimate

Results from the at-home test kit are available to HCPs and their patients through 1health
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.chromadex.com%2F&amp;esheet=54097998&amp;newsitemid=20240723490080&amp;lan=en-US&amp;anchor=ChromaDex+Corp.&amp;index=1&amp;md5=4de4481c5a75166f25ee8bc8e2c9a780">ChromaDex Corp.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, launches the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpro.truniagen.suitestore.dev%2Fniagen-plus-nad-plus-test-kit&amp;esheet=54097998&amp;newsitemid=20240723490080&amp;lan=en-US&amp;anchor=Niagen%2B+NAD%2B+Test+Kit&amp;index=2&amp;md5=39712b02001adc939e35c1ed5892f5e5">Niagen+ NAD+ Test Kit</a>&#x2A;, now available exclusively through the company's healthcare practitioner (HCP) channel. This innovative test kit provides practitioners with a reliable method for measuring patient blood NAD+ levels, helping them create more personalized and effective patient protocols using ChromaDex's NAD+-boosting HCP products, Tru Niagen&#xAE; and Niagen+.

ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively To Health Care Practitioners

Chromadex Says Board Appointed James Lee As Interim CFO

U.S. FDA-registered 503B outsourcing facility, Wells Pharma of Houston, will compound and distribute Niagen (nicotinamide riboside chloride) IV and injections to Cenegenics, Clean Market/NutriDrip, Drip Hydration, EXTEN IV, Kensho Wellbeing, The NAD MD, Next Health, The Remedy Room, Restore Hyper Wellness, and REVIV

ChromaDex To Ship Pharmaceutical-Grade Intravenous and Injectable Niagen At Wellness Clinics In August

ChromaDex Joins Russell 2000 Index As Part Of Annual Reconstitution; Inclusion Effective July 1, 2024

NR improved the six-minute walking distance and treadmill walking time for those with PAD

Milestone Phase II Clinical Study Demonstrates Niagen Patented Nicotinamide Riboside To Improve Functional Mobility For Individuals With Peripheral Artery Disease

ChromaDex Unveils Niagen+ With FDA Authorization; NRC To Be Available In IV, Shot, And Push Forms At Clinics Nationwide

Roth MKM analyst Sean McGowan maintains ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) with a Buy and maintains $6 price target.

Roth MKM Maintains Buy on ChromaDex, Maintains $6 Price Target

Shares of GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) fell sharply during Friday's session after the company released worse-than-expected first-quarter results before schedule and filed to <a href="https://www.benzinga.com/news/earnings/24/06/39224137/gamestop-releases-q1-results-ahead-of-roaring-kitty-event-files-prospectus-to-raise-capital-via-equ">sell up to 75 million shares</a>.
GameStop released its first-quarter 2024 results early Friday ahead of its scheduled June 11 date. The company reported net sales of $881.8 million, down from $1.237 billion year-over-year. The net sales total missed a consensus estimate of $995.3 million. The company reported a loss of 12 cents per share, missing the estimate of a loss of 9 cents per share, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
GameStop shares dipped 22.5% to $36.07 on Friday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Trinity Place Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPHS#NYSE">TPHS</a>) jumped 165.4% to $0.3220 after declining around 11% on Thursday.</li>
<li>Leafly Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFLY#NASDAQ">LFLY</a>) shares gained 91.6% to $3.87.</li>
<li>Venus Concept Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares jumped 87.5% to $1.1606 on continued upward momentum after the stock regained Nasdaq compliance.</li>
<li>Asensus Surgical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASXC#NASDAQ">ASXC</a>) climbed 40.1% to $0.3291 after the company announced it will be acquired by KARL STORZ for $0.35 per share in cash.</li>
<li>Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) gained 29.3% to $0.7032.</li>
<li>Geron Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) shares jumped 26% to $4.90 as the company reported the FDA approval of RYTELO&#x2122; (imetelstat), a first-in-class telomerase inhibitor, for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia.</li>
<li>China Liberal Education Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLEU#NASDAQ">CLEU</a>) gained 23.4% to $2.4899.</li>
<li>American Oncology Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AONC#NASDAQ">AONC</a>) gained 22.6% to $2.0850. American Oncology Network recently announced the opening of Low Country Radiation in Waycross, Georgia.</li>
<li>MAIA Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAIA#NASDAQ">MAIA</a>) rose 21.2% to $4.0249. The company unveiled compelling efficacy data from its Phase 2 THIO-101 clinical trial.</li>
<li>ChromaDex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) gained 19.2% to $3.41 after the company received exclusive FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Nicotinamide Riboside Chloride in the treatment of Ataxia Telangiectasia.</li>
<li>SunPower Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWR#NASDAQ">SPWR</a>) rose 18.8% to $4.11.</li>
<li>Oddity Tech Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) gained 18.3% to $43.49 after the company approved a share buyback and raised its Q2 guidance.</li>
<li>Universe Pharmaceuticals INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) jumped 14.3% to $2.64</li>
<li>Presto Automation Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRST#NASDAQ">PRST</a>) rose 14.1% to $0.0866 after declining 27% on Thursday.</li>
<li>Yext, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) gained 14.7% to $5.42. Yext is said to hire investment bankers to explore strategic alternatives, including a sale, Reuters reported.</li>
<li>Argan, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGX#NYSE">AGX</a>) jumped 11.1% to $76.78 after the company reported better-than-expected first-quarter financial results.</li>
<li>Planet Labs PBC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) gained 9.6% to $1.9950 following better-than-expected quarterly earnings.</li>
<li>Braze, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) rose 4.2% to $38.32 following better-than-expected first-quarter earnings.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Biomea Fusion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) shares dipped 65.6% to $3.87 after the United States Food and Drug Administration (FDA) imposed a full clinical hold on its Phase I/II trials for BMF-219, a diabetes treatment.</li>
<li>Barnes &amp; Noble Education, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNED#NYSE">BNED</a>) fell 35.3% to $0.2101 after the company announced final results of rights offering.</li>
<li>Scinai Immunotherapeutics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) fell 31.3% to $2.7474. Scinai Immunotherapeutics regained compliance with Nasdaq minimum bid price requirement.</li>
<li>Volcon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLCN#NASDAQ">VLCN</a>) fell 29.3% to $9.90. Volcon recently announced a 1-for-100 reverse stock split.</li>
<li>Latam Logistic Properties, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPA#NYSE">LPA</a>) shares fell 26.4% to $34.69 after jumping 49% on Thursday.</li>
<li>Hywin Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HYW#NYSE">HYW</a>) dipped 24.7% to $0.4670.</li>
<li>MicroAlgo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) shares fell 24.2% to $4.24. MicroAlgo recently announced that it entered into convertible note purchase agreements with certain investors.</li>
<li>Actelis Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASNS#NASDAQ">ASNS</a>) dipped 23% to $1.5101. Actelis announced closing of exercise of warrants for $3 million gross proceeds.</li>
<li>Semtech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) dipped 19.6% to $30.54 after the company announced it has appointed a new President and CEO and reaffirmed Q2 2025 guidance.</li>
<li>Gorilla Technology Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) fell 19.3% to $4.7699 after announcing a $12 million registered direct offering.</li>
<li>Bright Green Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGXX#NASDAQ">BGXX</a>) shares fell 18.7% to $0.2851 after declining around 8% on Thursday.</li>
<li>Seres Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) declined 18.7% to $0.6916. Canaccord Genuity analyst John Newman maintained Seres Therapeutics with a Buy and lowered the price target from $15 to $10.</li>
<li>CEA Industries Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEAD#NASDAQ">CEAD</a>) dipped 18% to $6.65.</li>
<li>Oil-Dri Corporation of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ODC#NYSE">ODC</a>) fell 17.3% to $68.57 following third-quarter results.</li>
<li>mF International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFI#NASDAQ">MFI</a>) fell 17.1% to $1.07.</li>
<li>Vail Resorts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) shares declined 13.6% to $167.50 after the company reported weaker-than-expected results for its third quarter on Thursday.</li>
<li>Samsara Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IOT#NYSE">IOT</a>) shares dipped 13.4% to $30.17 after the company reported first-quarter earnings.</li>
<li>Moving iMage Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MITQ#NYSE">MITQ</a>) fell 10.3% to $0.6001 after declining 33% on Thursday. Moving iMage Technologies was recently awarded a multi-million dollar contract.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) declined 10.2% to $17.56.</li>
<li>Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) fell 10.1% to $0.8001 as the company announced commencement of its previously announced rights offering.</li>
<li>Harmony Gold Mining Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMY#NYSE">HMY</a>) fell 9.2% to $8.36. Shares of precious metals companies traded lower amid a decline in gold and silver following US economic data.</li>
<li>Concrete Pumping Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBCP#NASDAQ">BBCP</a>) shares dipped 8% to $6.93 after posting weaker-than-expected second-quarter results.</li>
<li>Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) tumbled 8% to $24.75.</li>
<li>American Software, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMSWA#NASDAQ">AMSWA</a>) declined 7.5% to $9.55 following quarterly results. B. Riley Securities analyst Zach Cummings maintained American Software with a Buy and lowered the price target from $16 to $14.</li>
<li>DocuSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) shares fell 7.4% to $50.57. DocuSign reported better-than-expected earnings for its first quarter and the company&#8217;s board also authorized a $1 billion increase to its existing stock repurchase program. The company said it sees second-quarter billings in the range of $715 million to $725 million.</li>
<li>Impinj, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>) fell 7.1% to $153.03.</li>
<li>Gen Digital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEN#NASDAQ">GEN</a>) declined 5.2% to $24.13 after Morgan Stanley downgraded the stock from Overweight to Equal-Weight and lowered its price target from $28 to $27.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/06/39226995/over-2m-bet-on-this-tech-stock-check-out-these-4-stocks-insiders-are-buying">Over $2M Bet On This Tech Stock? Check Out These 4 Stocks Insiders Are Buying</a>

Intraday Update

Markets

Trading Ideas

AMSWA

AONC

ASNS

ASXC

BBCP

BGXX

BMEA

BNED

BRZE

CEA INDUSTRIES INC by CEA Industries Inc.

CEAD

CLEU

DOCU

FFIE

GERN

GRRR

LFLY

MAIA

MCRB

MITQ

MLGO

NVAX

PRST

SCNI

SIFY

SMTC

SPWR

TPHS

UPST

VERO

VLCN

YEXT

Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Chromadex (CDXC – Research Report) and keeping the price target at $6.00. Ram...

Buy Rating Affirmed on Chromadex's Turnaround and Growth Prospects

ChromaDex appoints Ozan Pamir as CFO

Chromadex ( ($CDXC) ) has shared an update. ChromaDex Corporation has onboarded Ozan Pamir as the new Chief Financial Officer, effective October 21...

ChromaDex Appoints Ozan Pamir as CFO for Future Growth

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Chromadex (CDXC – Research Report) and Anika Therape...

Analysts Are Bullish on Top Healthcare Stocks: Chromadex (CDXC), Anika Therapeutics (ANIK)

ChromaDex Q3 2024 Earnings Preview

Reports Q3 revenue $25.6M, consensus $23.64M. "We are proud to report our best quarter to date, achieving $25.6 million in revenue, an impressive 3...

ChromaDex reports Q3 EPS 2c, consensus 0c

Looking forward, for the full year, the company expects approximately 15% revenue growth year-over-year, driven by continued revenue growth through...

ChromaDex sees FY24 revenue growth 15%

ChromaDex GAAP EPS of $0.02 beats by $0.01, revenue of $25.58M beats by $1.71M

Chromadex ( ($CDXC) ) has provided an update. ChromaDex Corporation reported a strong third quarter in 2024, with a remarkable 31% increase in net ...

Chromadex Reports Strong Q3 2024 with 31% Sales Increase

ChromaDex Corporation ( ($CDXC) ) has released its Q3 earnings. Here is a breakdown of the information ChromaDex Corporation presented to its inves...

ChromaDex Reports Strong Q3 2024 Financial Results

ANIK

Press Releases

ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024

ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions

ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics

ChromaDex Appoints Ozan Pamir as Chief Financial Officer

ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference

Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)

ChromaDex to Participate in the 17th Annual LD Micro Main Event

ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

Comments

ChromaDex

ChromaDex (CDXC) Opciones

ChromaDex (NASDAQ:CDXC) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL